International cooperation to enhance efficient drug development

30 October 2019

NeuroDeRisk is a new international consortium in which Uppsala University, together with 17 partner organisations, will develop tools for better predictions of adverse effects that potential pharmaceuticals might have on the nervous system.

Within the project Cracking the code of neurotoxicity, 18 partners from academia and industry will develop new, sophisticated tools to better predict the potential adverse effects of pharmaceutical candidates on the nervous system. The work will be carried out within the framework of NeuroDeRisk, an international consortium that has received ten million Euro in funding from, among others, the Innovative Medicines Initiative.
“We currently lack sufficient effective models to assess which drugs will have adverse effects on the nervous system. Being granted 42 months of funding provides us the opportunity to further develop modern technology and thus contribute to better ways of reducing risks among pharmaceutical candidates already in preclinical research” says Jacques Richard, project manager at NeuroDeRisk.

Uppsala University, and the research group Translational Pharmacokinetics / Pharmacodynamics at the Faculty of Pharmacy – with Irena Loryan as head researcher – constitute Sweden's representatives in the consortium, that in the upcoming years will organize and expand existing knowledge, develop and improve tools and promote innovative methods in pharmaceutical development. The results of the project will be accumulated in an integrated toolbox that will streamline the pharmaceutical industry's research and development work, thus contributing to better and safer drug treatments.

More information  https://neuroderisk.eu/